Renuka Chintapalli

Receptor tyrosine kinase targeted therapies in glioblastoma: a systematic review

Introduction Glioblastoma is the most common primary central nervous system malignancy and has a median survival of 14.6 months. Receptor tyrosine kinase (RTKs) signalling consitutes one of the three major pathways driving glioblastoma, implicating them as a therapeutic target. H...